Application of KRT33B detection reagent in preparation of metabolic dysfunction related fatty liver disease diagnosis or risk assessment product

By detecting the expression level of KRT33B in serum, combined with monoclonal antibodies and enzyme-linked immunosorbent assay (ELISA), the problem of insufficient specificity and sensitivity in the diagnosis of MASLD was solved, realizing non-invasive, rapid and highly accurate diagnosis and risk assessment of MASLD, simplifying the diagnostic process and reducing costs.

CN119044506APending Publication Date: 2024-11-29XI AN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411202565.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing diagnostic biomarkers for MASLD lack specificity and sensitivity, have insufficient early diagnostic capabilities, exhibit variability among biomarkers, and have limited ability to monitor disease progression, leading to increased diagnostic complexity and costs, and low patient acceptance of imaging examinations and liver biopsies.

Method used

Using KRT33B detection reagents, this method detects the expression level of KRT33B in serum and combines it with monoclonal antibodies, enzyme-linked immunosorbent assay (ELISA), or protein mass spectrometry to provide a non-invasive, rapid, and highly sensitive diagnostic method for the diagnosis and risk assessment of metabolic dysfunction-related fatty liver disease.

Benefits of technology

It improves the diagnostic specificity and sensitivity of MASLD, simplifies the diagnostic process, reduces costs, increases patient acceptance and diagnostic accuracy, and is suitable for large-scale screening and monitoring of disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044506A_ABST
    Figure CN119044506A_ABST
Patent Text Reader

Abstract

The invention discloses application of a KRT33B detection reagent in preparation of a metabolic dysfunction related fatty liver disease diagnosis or risk assessment product, and belongs to the technical field of metabolic dysfunction related fatty liver disease diagnosis. Experiments find that the relative expression content of KRT33B in MASLD patients is increased, and compared with existing MASLD diagnostic markers ALT and AST, the KRT33B has high non-invasiveness, specificity, sensitivity and accuracy. Therefore, when the single serum marker KRT33B is used for diagnosing MASLD, the diagnosis process can be simplified, the feasibility is high, and the single serum marker KRT33B can be used for early accurate diagnosis of MASLD and can effectively monitor disease progression.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of diagnosis of metabolic dysfunction-related fatty liver disease, and specifically relates to the use of a KRT33B detection reagent in the preparation of a metabolic dysfunction-related fatty liver disease diagnosis or risk assessment product. Background Art

[0002] Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common liver disease. With the prevalence of obesity and diabetes, its incidence is gradually increasing. It not only affects the health of a large number of people, but also imposes a huge burden on the medical system and socio-economy. MASLD is often associated with metabolic syndromes such as obesity, diabetes, and hypertension, further increasing the risk of cardiovascular disease and cirrhosis. Although research on MASLD is constantly deepening, its exact cause and optimal treatment have not yet been fully clarified, which makes early screening and prevention particularly important. Especially in the context of rapid urbanization and lifestyle changes, the public's awareness and attention to MASLD urgently needs to be improved to promote early intervention and effective management to reduce the health hazards it brings.

[0003] The diagnosis of MASLD mainly relies on imaging examinations and liver biopsy. Liver biopsy is the "gold standard" for diagnosing fatty liver disease associated with metabolic dysfunction. However, since liver biopsy is an invasive and costly method, patients have poor acceptance. Therefore, non-invasive serum biomarker detection is a more ideal alternative. At present, liver function tests: such as ALT, AST and other enzyme activity assays are widely used for preliminary screening of MASLD, but they still have the following problems in the detection of MASLD: 1) Lack of specificity and sensitivity: These markers are not specific and sensitive enough for MASLD, and they will also be abnormal in other liver diseases and cannot accurately reflect the condition. 2) Lack of early diagnosis ability: Many serum markers mainly reflect the situation of late MASLD (such as MASH or cirrhosis), which is not very helpful for the diagnosis of early MASLD. This limits the possibility of early intervention and treatment. 3) Variability between markers: There may be large variability between different serum markers, which makes it difficult for a single marker to fully and accurately reflect the disease condition. Therefore, multiple markers may be required for combined detection, which increases the complexity and cost of diagnosis. 4) Lack of standardization: The methods and standards for serum marker detection may vary between different laboratories, which affects the comparability and reliability of the results. 5) Limited ability to monitor disease progression: Although some serum markers can reflect the presence of the disease, they are limited in their effectiveness in monitoring disease progression and responding to treatment. This means that even after the diagnosis of MASLD, it is difficult to accurately assess changes in disease status. There are currently no specific markers that can be used in clinical practice. Therefore, it is urgent to find a new specific serum marker that can be used to diagnose MASLD.

[0004] Keratin 33B (KRT33B) is encoded by a gene on chromosome 17 and is a member of the keratin family. Its expression is highly tissue-specific and is mainly found in the skin and hair. When it is translocated, it often indicates the occurrence of disease. Currently, no studies have reported the relationship between KRT33B and MASLD. Summary of the invention

[0005] In order to overcome the shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide a detection reagent for KRT33B for use in the preparation of a metabolic dysfunction-related fatty liver disease diagnosis or risk assessment product, so as to solve the technical problems of the existing MASLD diagnostic markers lacking specificity and sensitivity, early diagnosis capability and standardization, variability between markers and limited ability to monitor disease progression.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The first aspect of the present invention discloses the use of a KRT33B detection reagent in the preparation of a metabolic dysfunction-related fatty liver disease diagnosis or risk assessment product.

[0008] Preferably, the KRT33B detection reagent is a detection reagent for detecting whether the KRT33B protein is expressed.

[0009] Preferably, the expression level of KRT33B is increased in patients with metabolic dysfunction-related fatty liver disease.

[0010] Preferably, the detection sample of the detection reagent is serum.

[0011] Preferably, the KRT33B is human KRT33B.

[0012] Preferably, the detection reagent comprises a monoclonal antibody detection reagent, an enzyme-linked immunosorbent assay reagent or a protein mass spectrometry detection reagent.

[0013] Preferably, the product is a preparation, a chip, a test strip or a kit.

[0014] The second aspect of the present invention discloses a kit for detecting fatty liver disease associated with metabolic dysfunction, comprising a reagent for detecting the expression level of KRT33B.

[0015] The third aspect of the present invention discloses a detection system for metabolic dysfunction-related fatty liver disease, comprising:

[0016] Data storage module: used to store the expression information of metabolic dysfunction-related fatty liver disease diagnostic markers, wherein the diagnostic marker is KRT33B;

[0017] Data analysis module: Calculate the risk of metabolic dysfunction-related fatty liver disease based on the expression information of metabolic dysfunction-related fatty liver disease diagnostic markers;

[0018] Result output module: outputs the results of the data analysis module.

[0019] Preferably, in the test results, the expression level of KRT33B is significantly upregulated, which is determined to be a high risk of fatty liver disease associated with metabolic dysfunction.

[0020] The fourth aspect of the present invention discloses a diagnostic marker group for metabolic dysfunction-related fatty liver disease, comprising KRT33B, ALT and AST.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The application of the detection reagent of KRT33B provided by the present invention in the preparation of a diagnostic or risk assessment product for metabolic dysfunction-related fatty liver disease. Experiments have shown that the relative expression level of KRT33B in MASLD patients is increased, and compared with the existing MASLD diagnostic markers ALT and AST, it has high specificity, sensitivity and accuracy, indicating that KRT33B has the potential to accurately diagnose MASLD early and can effectively monitor disease progression. When diagnosing metabolic dysfunction-related fatty liver disease (MASLD), using a single serum marker KRT33B as a detection method has obvious advantages. Specifically as follows:

[0023] (1) Simplify the diagnostic process

[0024] Simple operation: Blood test is a routine clinical examination, which is simple and easy to perform.

[0025] Rapid Results: Single serum marker tests provide rapid results, helping to speed up the initial diagnosis process compared to other more complex or time-consuming diagnostic methods.

[0026] Reduced need for other tests: If a single marker could provide highly accurate diagnostic information, it could reduce the need for more expensive, complex, or invasive diagnostic methods, such as liver biopsy.

[0027] (2) Strong feasibility

[0028] Widely available: Blood tests are common at all levels of healthcare and can be easily applied in large-scale or primary health care settings.

[0029] Cost-effectiveness: Compared with high-cost imaging tests (such as MRI or CT scans) and invasive liver biopsies, serum marker testing is low-cost, which is particularly important in resource-limited settings.

[0030] (3) Non-invasive

[0031] Patient-friendly: Blood testing is a non-invasive test with almost no risk to patients, making it easier for patients to accept than invasive tests such as liver biopsy.

[0032] Good reproducibility: Blood tests can be easily repeated, making it easier to monitor disease progression or treatment effectiveness.

[0033] (4) As a screening tool

[0034] Large-scale screening: Single serum marker testing can be used as a primary tool for large-scale screening of MASLD to help identify high-risk individuals who require further evaluation.

[0035] Initial evaluation: Blood testing can be an effective initial evaluation tool prior to complex and expensive diagnostic testing to help decide which patients require further detailed investigations.

[0036] (5) Improve diagnostic accuracy

[0037] Reduce misdiagnosis and missed diagnosis: High sensitivity means lower missed diagnosis rate, while high specificity means lower misdiagnosis rate. This is critical to ensure patients receive the correct diagnosis and subsequent treatment.

[0038] Wide application: It can be easily applied on a large scale in primary and frontline medical institutions to improve the screening rate of MASLD.

[0039] (6) Improve patient compliance

[0040] Reduced patient burden: Non-invasive blood tests are more acceptable to patients than more invasive methods such as liver biopsy, and may improve patient compliance with regular testing and treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 The results of Western blot experiments to evaluate the serum levels of KRT33B in healthy volunteers and MASLD patients; (a) representative Western blot images (upper panel) and Ponceau red staining (lower panel) of the serum levels of KRT33B in healthy volunteers and MASLD patients; (b) statistical Western blot images of the serum levels of KRT33B in healthy volunteers and MASLD patients (n=42 / group);

[0042] Figure 2 The results of the correlation analysis between serum KRT33B and liver damage markers ALT and AST are shown in the figure; (a) the results of the correlation analysis between serum KRT33B content and liver damage marker ALT in healthy volunteers and MASLD patient groups (n=84); (b) the results of the correlation analysis between serum KRT33B content and liver damage marker AST in healthy volunteers and MASLD patient groups (n=84);

[0043] Figure 3 The ROC curve analysis results of serum ALT, AST and KRT33B in healthy volunteers and MASLD patients; (a) ALT, (b) AST, (c) KRT33B;

[0044] Figure 4 Schematic diagram of the detection system for metabolic dysfunction-related fatty liver disease. DETAILED DESCRIPTION

[0045] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.

[0046] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.

[0047] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values ​​within the range (including integers and fractions).

[0048] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”

[0049] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.

[0050] The present invention provides an application of a KRT33B detection reagent in the preparation of a metabolic dysfunction-related fatty liver disease diagnosis or risk assessment product, wherein the metabolic dysfunction-related fatty liver disease is diagnosed by detecting the content of KRT33B in serum and the disease progression is judged. The KRT33B is human KRT33B.

[0051] Herein, the biomarker KRT33B is used in combination with other known serum markers (such as ALT, AST, liver fibrosis markers, etc.) to improve the accuracy and reliability of diagnosing MASLD / NAFLD. The specific application of this combination method should be considered to be within the scope of this specification.

[0052] In this article, the detection method involved can be used to establish diagnostic guidelines for MASLD / NAFLD based on KRT33B levels, including determining thresholds for normal and abnormal levels. This may involve large-scale population studies to calibrate the relationship between KRT33B levels and the clinical diagnosis of MASLD / NAFLD, taking into account the effects of age, gender, and other relevant factors.

[0053] Herein, specific methods or test kits capable of detecting the level of KRT33B in serum include, but are not limited to, the development of monoclonal antibodies, the design and development of detection methods such as enzyme-linked immunosorbent assay (ELISA), protein mass spectrometry, or the innovative application of other biochemical methods to achieve high sensitivity and specificity detection of KRT33B.

[0054] In this article, KRT33B levels can be used to monitor MASLD / NAFLD disease progression or response to treatment, and changes in KRT33B levels can reflect changes in the state of metabolic dysfunction-related fatty liver disease or predict the prognosis of metabolic dysfunction-related fatty liver disease, so as to be used for monitoring and prognostic evaluation of metabolic dysfunction-related fatty liver disease.

[0055] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0056] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples, unless otherwise specified, are conventional commercial products, and their specifications are conventional specifications in the art.

[0057] The serum samples in the following examples were all from the First Affiliated Hospital of Xi'an Jiaotong University and the Second Affiliated Hospital of Xi'an Jiaotong University. The study procedures have been approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University and the Second Affiliated Hospital of Xi'an Jiaotong University and are in compliance with the Declaration of Helsinki.

[0058] Example 1

[0059] 1. Western blot assay to evaluate KRT33B serum levels in healthy volunteers and MASLD patients

[0060] A. Centrifuge the collected 84 serum samples at 3000g for 10 min, take 2 μL of the supernatant, add 50 μL of PBS, and mix thoroughly; add 12.5 μL of 5× protein loading buffer and mix thoroughly; denature in a metal bath at 100℃ for 10 min; after denaturation, immediately insert into crushed ice.

[0061] B. Pre-made SDS-PAGE gel. ① Prepare 5mL of 10% lower gel: 1.3mL of H2O; 1.7mL of 30% Acrylamide; 1.9mL of 1.0M Tris (pH 8.8); 50μL of 10% SDS; 50μL of 10% ammonium persulfate; 2μL of TEMED; mix thoroughly, add separation gel to the gel plate, and press it flat with distilled water. After a clear boundary appears between the distilled water and the separation gel, pour out the distilled water and absorb the remaining distilled water with filter paper. ② Prepare 2 mL of 5% upper gel: 1.4 mL of H2O; 330 μL of 30% Acrylamide; 250 μL of 1.0 M Tris (pH 8.8); 20 μL of 10% SDS; 20 μL of 10% ammonium persulfate; 2 μL of TEMED; mix thoroughly, add separation gel to the gel plate, insert the comb, and wait for about 20 minutes for it to solidify.

[0062] C. Sample loading. Install the pre-made SDS-PAGE gel on the gel plate and place it in the electrophoresis tank. Dilute 10× SDS-PAGE electrophoresis buffer to 1× and add it to the inner tank (filled up) and outer tank of the electrophoresis tank. Remove the comb in the concentrated gel to expose the sample wells, and add 5μL of the prepared sample and 3μL of protein pre-stained marker to the gel wells.

[0063] D. Electrophoresis: The voltage of the concentrated gel is ≤80V and the electrophoresis is continued until the separation gel is reached (about 50 minutes). The voltage of the separation gel is ≤120V and the electrophoresis is stopped until the gel plate is 2 cm from the bottom (about 1 hour).

[0064] E. Transfer. Cut the upper and lower filter pads required for transfer and soak them in transfer buffer for about 10 minutes. Cut the PVDF membrane and activate it in 100% methanol for 10 seconds, then transfer it to transfer buffer and soak it for 10 minutes. Cut the SDS-PAGE gel according to the protein pre-stained marker, retain the target protein area, put it into the transfer buffer, and prepare for transfer. Lay the lower filter paper pad, PVDF membrane, SDS-PAGE gel, and upper filter paper pad in order from bottom to top to form a "sandwich structure", and drive out the bubbles in the middle of the "sandwich structure". After installing the semi-dry transfer instrument, transfer the membrane at 15V for 70 minutes.

[0065] F. Ponceau staining. After the transfer is completed, remove the PVDF membrane and observe the clear protein pre-stained marker. Place the membrane in distilled water and shake it for 5 minutes to remove the residual transfer buffer. Add Ponceau staining solution to cover the PVDF membrane and shake it slowly for 5 minutes. After taking pictures with white light (representative staining is shown in Figure 2), the membrane is washed with distilled water and shaken for 5 minutes. Figure 1 The membrane was placed in 1×PBS and washed on a shaker for 5 min, and this was repeated 3 times.

[0066] G. Blocking: Soak the membrane in 1×TBST containing 5% skimmed milk powder and shake gently for 2 h.

[0067] H. Primary antibody incubation. Dilute the primary antibody (1:1000) according to the primary antibody dilution ratio provided in the KRT33B antibody manual, and incubate the PVDF membrane at 4°C for 14 hours. Remove the PVDF membrane and wash it with 1×TBST on a shaker at room temperature, 4 times at 165 rpm, 10 minutes each time.

[0068] I. Secondary antibody incubation. Dilute the secondary antibody (1:5000) according to the secondary antibody instructions and incubate at room temperature for 2 hours. Remove and wash, shake and wash with 1×TBST on a shaker for 3 times, 10 minutes each time, and finally wash with 1×TBS on a shaker for 1 time, 10 minutes.

[0069] J. Exposure and development. Prepare the ECL luminescent solution, select appropriate amounts of solution A and solution B according to the size of the PVDF membrane, mix them in equal volumes, mix them evenly, drop them onto the PVDF membrane, fill it up, protect it from light, and place it in a chemical luminescent imager for detection (representative results are shown in Figure 2). Figure 1 (as shown in a in the figure).

[0070] K. Data analysis. Image-J software was used to analyze the grayscale of all sample protein bands. The relative expression of KRT33B in MASLD patients was found to be elevated based on the ratio of the grayscale to the internal reference (e.g. Figure 1 (as shown in b).

[0071] 2. Detect the expression levels of serum liver damage markers ALT and AST, and perform Pearson correlation analysis with serum KRT33B

[0072] A. According to the instructions of the Alanine Aminotransferase (ALT / GPT) Test Kit (Cat. No. C009-2-1) of Nanjing Jiancheng Bioengineering Institute, the ALT content of the 84 sera collected above was tested. Figure 2Figure a shows the correlation analysis results of KRT33B serum levels and liver damage marker ALT in healthy volunteers and MASLD patients (n=84). Pearson correlation analysis results showed that the correlation coefficient between KRT33B and ALT was 0.2137, indicating a certain positive correlation, but the correlation was weak. The P value was 0.0509, close to the significance level, suggesting that a significant correlation may be found with a larger sample size.

[0073] B. According to the instructions of the aspartate aminotransferase (AST / GOT) test kit (Cat. No. C010-2-1) of Nanjing Jiancheng Bioengineering Research Institute, the AST content of the 84 sera collected above was tested. Figure 2 Figure b shows the correlation analysis results of KRT33B serum levels and liver damage marker AST in healthy volunteers and MASLD patients (n=84). Pearson correlation analysis results showed that the correlation coefficient between KRT33B and AST was 0.2395, and the P value was 0.0347, indicating that there was a significant but weak positive correlation between KRT33B and AST. In other words, when the serum KRT33B content increased, the AST level also increased to a certain extent, indicating that the severity of liver damage was positively correlated with the serum content of KRT33B.

[0074] C. The above-mentioned serum levels of ALT, AST and KRT33B were subjected to ROC curve analysis. The results showed that the area under the ROC curve (AUC) of serum ALT was 0.7574 ( Figure 3 In a), the AUC value of serum AST was 0.7015 ( Figure 3 In b), the AUC value of serum KRT33B was 0.9590 ( Figure 3 (c) AUC values ​​range from 0.5 to 1.0. When AUC>0.5, the closer the AUC is to 1, the better the diagnostic effect. AUC has low accuracy when it is 0.5-0.7, has certain accuracy when it is 0.7-0.9, and has high accuracy when it is above 0.9. Our results show that the diagnostic accuracy of KRT33B is significantly better than that of traditional serum markers ALT and AST.

[0075] In summary, serum KRT33B is expected to become a single serum biomarker for the clinical diagnosis of MASLD.

[0076] Example 2

[0077] A kit for detecting fatty liver disease associated with metabolic dysfunction includes serum primers, and may also have commonly used enzymes and / or reagents required for detecting the expression level of KRT33B. The specific components can be selected according to the specific experimental method. These enzymes and / or reagents are well known to those skilled in the art. In addition, there may be standards and controls (such as quantitatively standardized normal human samples, etc.) and normal reference values. The value of this kit is that only serum is required but no other tissue samples are required, and high sensitivity and specificity detection of KRT33B is achieved through detection methods such as monoclonal antibodies, enzyme-linked immunosorbent assay or protein mass spectrometry. Therefore, putting this kit into actual production can help guide clinical auxiliary early diagnosis.

[0078] Example 3

[0079] A detection system for fatty liver disease associated with metabolic dysfunction, such as Figure 4 As shown, including:

[0080] Data storage module: used to store the expression information of KRT33B, a diagnostic marker for fatty liver disease associated with metabolic dysfunction;

[0081] Data analysis module: Calculate the risk of metabolic dysfunction-related fatty liver disease based on the expression information of metabolic dysfunction-related fatty liver disease diagnostic markers;

[0082] Result output module: outputs the results of the data analysis module.

[0083] It can be understood that the detection system for metabolic dysfunction-related fatty liver disease provided by the present invention corresponds to the increased expression level of KRT33B in patients with metabolic dysfunction-related fatty liver disease provided in the aforementioned embodiment, and can be used for the diagnosis or risk assessment of metabolic dysfunction-related fatty liver disease.

[0084] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. Application of KRT33B detection reagent in the preparation of diagnostic or risk assessment products for fatty liver disease associated with metabolic dysfunction.

2. The use according to claim 1, characterized in that: KRT33B expression levels are elevated in patients with metabolic dysfunction-associated fatty liver disease.

3. The use according to claim 1, characterized in that: The detection sample of the detection reagent is serum.

4. The use according to claim 1, characterized in that: The KRT33B is human KRT33B.

5. The use according to claim 1, characterized in that: The detection reagents include monoclonal antibody detection reagents, enzyme-linked immunosorbent assay reagents or protein mass spectrometry detection reagents.

6. The use according to any one of claims 1 to 5, characterized in that: The product is a preparation, a chip, a test strip or a test kit.

7. A kit for detecting fatty liver disease associated with metabolic dysfunction, characterized in that: Reagents for detecting the expression level of KRT33B are included.

8. A detection system for fatty liver disease associated with metabolic dysfunction, characterized in that: include: Data storage module: used to store the expression information of metabolic dysfunction-related fatty liver disease diagnostic markers, wherein the diagnostic marker is KRT33B; Data analysis module: Calculate the risk of metabolic dysfunction-related fatty liver disease based on the expression information of metabolic dysfunction-related fatty liver disease diagnostic markers; Result output module: outputs the results of the data analysis module.

9. The detection system for metabolic dysfunction-related fatty liver disease according to claim 8, characterized in that: In the test results, the expression level of KRT33B was significantly upregulated, which was judged as a high risk of fatty liver disease related to metabolic dysfunction.

10. A diagnostic marker panel for fatty liver disease associated with metabolic dysfunction, characterized in that: Including KRT33B, ALT and AST.